Horse Anti-Thymocyte Globulin (hATG)
Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisolone, and GCSF (Filgrastim or Pegfilgrastim) in Patients With Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 140 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Collaborators
- National Cancer Institute (NCI)
- Tags
- White Blood Cell Stimulant, Steroid
- Trial Type
- Treatment
- Last Update
- 10 months ago
- SparkCures ID
- 1504
- NCT Identifier
- NCT01624805
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.